PROVIDENCE – EpiVax Inc. is partnering with Intravacc to develop a universal vaccine for betacoronaviruses, including SARS-CoV-2.
The project is funded by the Coalition for Epidemic Preparedness Innovations under its 2021 call for proposals, which allocates up to $200 million in funding for the development of broadly protected coronavirus vaccines.
ISO 9001:2026: A Practical Opportunity to Build for What’s Next
For Rhode Island manufacturers, ISO 9001 has been much more than a certificate on the…
Learn More
“We sincerely appreciate the opportunity to apply our advanced vaccine design tools to a problem of global significance,” said Dr. Annie S. De Groot, CEO of Providence-based EpiVax.
Intravacc, a Dutch vaccine clinical development and manufacturing organization, was awarded $4.8 million for its vaccine candidate “Avacc 101,” an intranasal vaccine designed to protect against multiple betacoronaviruses, including SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
EpiVax will work as a subgrantee in the project, using its silico vaccine design toolkit “iVAX” to carry out the vaccine epitope selection portion of the project.
Claudia Chiappa is a PBN staff writer. You may contact her at Chiappa@PBN.com.
